Septerna director granted 15,000 stock options

Septerna, Inc. reported that director Jake Simson received a grant of stock options covering 15,000 shares of common stock at an exercise price of $37.34 per share.

Rhea-AI Filing Summary

Septerna, Inc. reported that director Jake Simson received a grant of stock options covering 15,000 shares of common stock at an exercise price of $37.34 per share. The options vest in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided he continues to serve until that date.

Under an arrangement with RA Capital Management, L.P., Simson holds this option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P. Any net cash or stock from exercising the option must be turned over to the adviser to offset advisory fees, and Simson disclaims beneficial ownership of the option and underlying shares.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Simson Jake

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	15,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 15,000 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
2. F2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund") and R.A. Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Key Figures

Option grant size: 15,000 options Exercise price: $37.34 per share Underlying shares: 15,000 shares +3 more

6 metrics

Option grant size 15,000 options Stock Option (Right to Buy) granted to director

Exercise price $37.34 per share Conversion or exercise price of granted options

Underlying shares 15,000 shares Common stock underlying the option

Post-transaction derivative holdings 15,000 options Total options following transaction

Option vesting date June 26, 2027 Vests earlier of this date or next annual meeting

Option expiration June 25, 2036 Expiration date of the stock option grant

Key Terms

Stock Option (Right to Buy), beneficial ownership, annual meeting of stockholders, advisory fees, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

beneficial ownership financial

"The Reporting Person therefore disclaims beneficial ownership of the option"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

advisory fees financial

"which will offset advisory fees owed by the Fund and the Nexus Fund III"

Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.

continued service financial

"subject to the Reporting Person's continued service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Septerna (SEPN) director Jake Simson receive in this Form 4 filing?

Septerna director Jake Simson received a grant of stock options for 15,000 shares of common stock at an exercise price of $37.34 per share. These options represent compensation and do not reflect an open-market share purchase or sale.

When do Jake Simson’s Septerna (SEPN) stock options vest?

The options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual meeting of stockholders. Vesting requires Simson’s continued service to Septerna through the applicable vesting date as disclosed.

Who ultimately benefits from the Septerna (SEPN) stock options reported by Jake Simson?

The options are held for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P. Under an arrangement with RA Capital Management, L.P., any net cash or stock from exercising the options offsets advisory fees owed by those funds.

Does Jake Simson claim beneficial ownership of the Septerna (SEPN) options and shares?

No. The filing states that Simson is obligated to turn over any net cash or stock from exercising the options to RA Capital Management, L.P. As a result, he expressly disclaims beneficial ownership of the option and the underlying common stock.

What is the expiration date of the Septerna (SEPN) stock options granted to Jake Simson?

The stock options expire on June 25, 2036, giving a long-dated window to exercise at the fixed price of $37.34 per share, subject to vesting and the existing arrangement with RA Capital Management, L.P.

How many Septerna (SEPN) derivative securities does the Form 4 show after this grant?

Following this grant, the Form 4 shows 15,000 stock options outstanding for Jake Simson. These options are tied to an equal number of underlying Septerna common shares, with no additional derivative positions listed in this specific filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 07:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simson Jake

(Last) (First) (Middle)

C/O SEPTERNA, INC.

250 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Septerna, Inc. [ SEPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$37.34	06/26/2026		A		15,000		(1)	06/25/2036	Common Stock	15,000	$0	15,000	D(2)

Explanation of Responses:

1. The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund") and R.A. Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Remarks:

Exhibit 24.2 - Substitute Power of Attorney

	/s/ Mark A. Wilson, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)